Business Context and Reporting Period
Company: Biogen Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Biogen is a global biopharmaceutical company focused on neurology, specialized immunology, and rare diseases. Key marketed products include VUMERITY, TYSABRI, and TECFIDERA (MS); SPINRAZA (SMA); SKYCLARYS (FA); and QALSODY (ALS). The company maintains significant collaborations with Eisai (LEQEMBI for Alzheimer's), Supernus (ZURZUVAE for PPD), and Genentech (anti-CD20 therapeutic programs).
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $9,890.6 | $9,675.9 | +2.2% |
| Net Income | $1,292.9 | $1,632.2 | -20.8% |
| Diluted EPS | $8.79 | $11.18 | -21.4% |
| Operating Cash Flow | $2,204.6 | $2,875.5 | -23.3% |
| Cash & Marketable Securities | $4,247.6 | $2,375.0 | +78.8% |
| Total Debt (Notes Payable) | $6,286.8 | $6,295.8 | -0.1% |
| Working Capital | $5,624.7 | $1,928.0 | +191.7% |
Revenue Composition: Product revenue decreased 1.3% to $7.12 billion. Revenue from anti-CD20 therapeutic programs increased 6.3% to $1.86 billion. Alzheimer's collaboration revenue (LEQEMBI) grew significantly to $177.7 million.
Material Changes vs. Prior Period
- Revenue Drivers: Total revenue growth was driven by a 6.3% increase in anti-CD20 revenue and a 196.7% increase in Alzheimer's collaboration revenue. This offset a 7.1% decline in Multiple Sclerosis (MS) product revenue, primarily due to generic competition for TECFIDERA and biosimilar competition for TYSABRI.
- Expense Increases: Total cost and expense increased 7.3% to $8.33 billion. Notable increases included:
- Acquired IPR&D, Upfront and Milestone Expense: Increased $410.3 million to $471.8 million due to significant upfront payments for collaborations (Stoke, Vanqua, Dayra) and the Alcyone acquisition.
- Cost of Sales: Increased $93.8 million, driven by a $104.9 million litigation charge and product mix changes.
- Other (Income) Expense: Included $139.5 million in litigation-related expenses.
- Profitability: Net income declined 20.8% primarily due to the surge in upfront milestone payments and litigation costs, despite a 10.2% reduction in core R&D expense (partially offset by $200 million in Royalty Pharma funding).
- Liquidity: Cash and marketable securities increased by $1.87 billion, bolstered by operating cash flow and the issuance of $1.75 billion in Senior Notes (used to redeem maturing debt).
Guidance, Outlook, and Risks
- Outlook: Management expects MS revenue to continue declining in 2026 due to accelerating generic competition. Rare disease revenue is expected to grow driven by SKYCLARYS and QALSODY launches. R&D expense is expected to increase slightly in 2026 with investments in late-stage programs.
- Key Developments:
- Acquisitions: Completed acquisition of Alcyone Therapeutics ($85 million consideration) for pediatric CNS delivery platforms.
- Collaborations: Entered major collaborations with Stoke (zorevunersen for Dravet syndrome, $165 million upfront), Vanqua (C5aR1 antagonist, $70 million upfront), and Dayra (oral macrocyclic peptides, $50 million upfront).
- Regulatory: FDA accepted supplemental BLA for LEQEMBI subcutaneous autoinjector (PDUFA May 2026). EC granted marketing authorization for high-dose SPINRAZA.
- Risks and Contingencies:
- Competition: Significant revenue erosion from TECFIDERA generics and TYSABRI biosimilars. Biosimilar competition for RITUXAN continues to impact collaboration profits.
- Legal: Recorded $139.5 million for litigation matters, including an agreement in principle to resolve Convergence acquisition claims and a $124.3 million judgment against Biogen in Genentech litigation (appeal pending).
- Regulatory/Pricing: Ongoing uncertainty regarding the Inflation Reduction Act (IRA) Medicare Part D redesign and potential Most-Favored-Nation (MFN) pricing policies. The IRA had a modest net unfavorable impact of ~$90 million on 2025 revenue.
- Manufacturing: Risks related to reliance on third-party suppliers and single-source providers for raw materials.
Investor Verification Checklist
- TECFIDERA & TYSABRI Decline: Verify the trajectory of revenue decline in the MS portfolio against generic and biosimilar market share data.
- LEQEMBI Commercialization: Assess the impact of the subcutaneous autoinjector approval and the ongoing arbitration with Eisai regarding European commercialization responsibilities.
- Upfront Payment Sustainability: Evaluate the cash burn rate associated with the $471.8 million in upfront/milestone expenses and the pipeline success probability of newly acquired assets (Stoke, Vanqua, Alcyone).
- Litigation Exposure: Monitor the status of the Genentech appeal ($124.3 million judgment) and the Convergence shareholder resolution.
- IRA Impact: Track the full implementation of the IRA Medicare Part D redesign and its specific impact on SKYCLARYS and MS product margins in 2026.
- Debt Structure: Confirm the terms and interest rate exposure of the new 2025 Senior Notes issued to refinance maturing debt.